- Clinical trial of dostarlimab cured 18 patients in the US of colorectal cancer
- One researcher said that it was the ‘first time this has happened’ in a cancer trial
- It is still too early to declare the drug a cancer cure because the trial was small
- Doctors are expanding trial for gastric, prostate and pancreatic cancer patients
A recent drug trial administered to a handful of cancer patients had the surprising result of eliminating the disease in every participant involved.
The study was conducted on 18 rectal cancer patients at Memorial Sloan Kettering Cancer Center in Manhattan and had a 100 percent success rate, according to a paper published Sunday in the New England Journal of Medicine.
“I believe this is the first time this has happened in the history of cancer,” Dr. Luis A. Diaz Jr, the author of the paper, told the New York Times.
The drug, dostarlimab, was administered to each patient every 3 weeks for 6 months.
Participants in the study were suffering from cancer of the colon and were given alternatives such as chemotherapy or a difficult surgery that could potentially lead to bowel or urinary dysfunction. Some patients are required to use a colostomy bag due to treatment, the Times said.
At the conclusion of the drug trial, however, the patients were spared the agony of potentially damaging treatment when they showed no evidence of a tumor after receiving an MRI, rectal examination and biopsy.
“There were a lot of happy tears,” Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center told the Times.
In addition to not needing further treatment to eradicate the disease, there were no instances of a recurrence of cancer in the patients during follow-up appointments from 6 to 25 months after the trial ended.
One participant, Sascha Roth, told the Times that she planned to move to Manhattan for chemotherapy and radiation treatment before the study began.
Then doctors gave her the good news — the trial worked and she was cancer-free.
“I told my family,” Roth said. “They didn’t believe me.”